Targeting Reward Circuits: Psilocybin as a Novel Therapy for Residual Anhedonia
The primary objective is to evaluate whether a single dose of psilocybin (25 mg), compared to placebo, can restore fronto-striatal reward circuit function and thereby improve anhedonia and emotional blunting in individuals with residual symptoms despite ongoing SSRI or SNRI treatment. This will be assessed using precision functional mapping (PFM), task-based fMRI, and clinical rating scales (DARS).
- Record type
- Registered clinical trial
- Status
- recruiting
- Phase
- Phase 1
- Institution
- NYU Langone Health
- Principal investigator
- Joshua Siegel, MD, PhD
- Start date
- 2026-07-01
- End date
- 2030-09-30
- Registry ID
- NCT07607938
Listed in the DMT Code trials, studies and experiments observatory. Record type: Registered clinical trial. Only registered clinical trials carry clinical authority in this record set.